The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2023

Filed:

Feb. 24, 2017
Applicant:

The Rockefeller University, New York, NY (US);

Inventors:

Ali Brivanlou, NY, NY (US);

Albert Ruzo, New York, NY (US);

Alessia Deglincerti, New York, NY (US);

Tomomi Haremaki, New York, NY (US);

Fred Etoc, New York, NY (US);

Assignee:

The Rockefeller University, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/02 (2006.01); G01N 33/50 (2006.01); C12Q 1/18 (2006.01); C12N 15/09 (2006.01); C12N 5/0735 (2010.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5073 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07K 14/47 (2013.01); C12N 5/0606 (2013.01); C12N 15/09 (2013.01); C12Q 1/02 (2013.01); C12Q 1/025 (2013.01); C12Q 1/18 (2013.01); C12N 2503/02 (2013.01); C12N 2510/00 (2013.01);
Abstract

Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disease form of the HTT gene comprises a polyQ repeat of at least 40 glutamines at the N-terminus of the Huntingtin protein (HTT). The cell lines of the disclosure comprise genetically-defined alterations made in the endogenous HTT gene that recapitulate Huntington's Disease in humans. Furthermore, the cell lines have isogenic controls that share a similar genetic background. Differentiating cell lines committed to a neuronal fate and fully differentiated cell lines are also provided and they also display phenotypic abnormalities associated with the length of the polyQ repeat of the HTT gene. These cell lines are used as screening tools in drug discovery and development to identify substances that fully or partially revert these phenotype abnormalities.


Find Patent Forward Citations

Loading…